Online inquiry

IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7316MR)

This product GTTS-WQ7316MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets FGFR2 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000141.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2263
UniProt ID P21802
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7316MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15564MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ13358MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ13248MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ7091MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ3508MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ7703MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ476MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ5915MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CK-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW